Drugs

FDA Drug Safety Podcasts

Drug Safety Podcast Banner Graphic

The FDA Drug Safety Podcasts are produced by FDA's Center for Drug Evaluation and Research (CDER). They provide emerging safety information about drugs in conjunction with the release of Drug Safety Communications.    

Latest Drug Safety Podcasts

TitleDateLink to PodcastLink to Transcript
FDA identifies no harmful effects to date with brain retention of gadolinium-based contrast agents for MRIs; review to continue May 22, 2017 Listen to This Podcast
Run Time:
00:3:00
Transcript 
FDA confirms increased risk of leg and foot amputations with the diabetes medicine canagliflozin (Invokana, Invokamet, Invokamet XR) May 16, 2017 Listen to This Podcast
Run Time:
00:3:00
 Transcript
FDA approves label changes for use of general anesthetic and sedation drugs in young childrenApril 27, 2017Listen to This Podcast
Run Time:
00:3:00
Transcript
FDA restricts use of prescription codeine pain and cough medicines and tramadol pain medicines in children; recommends against use in breastfeeding womenApril 20, 2017Listen to This Podcast
Run Time:
00:3:00
Transcript
FDA warns about increased risk of serious pancreatitis with irritable bowel drug Viberzi (eluxadoline) in patients without a gallbladderMarch 15, 2017Listen to This Podcast
Run Time:
00:3:00
Transcript
FDA warns about rare but serious allergic reactions with the skin antiseptic chlorhexidine gluconateFebruary 2, 2017  Listen to This Podcast
Run Time:
00:3:00
Transcript 
FDA revises description of mental health side effects of stop-smoking medicines Chantix and Zyban to reflect clinical trial findingsDecember 16, 2016Listen to This Podcast
Run Time:
00:3:00
Transcript
FDA review results in new warnings about using general anesthetics and sedation drugs in young children and pregnant womenDecember 14, 2016Listen to This Podcast
Run Time:
00:3:00
Transcript 
Updated FDA review concludes that use of pioglitazone may be linked to an increased risk of bladder cancerDecember 12, 2016Listen to This Podcast
Run Time:
00:3:00
Transcript 
FDA warns about the risk of hepatitis B reactivating in some patients treated with direct-acting antivirals for hepatitis COctober 4, 2016Listen to This Podcast
Run Time:
00:3:00
Transcript
FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warningAugust 31, 2016Listen to This Podcast
Run Time:
00:3:00
Transcript
FDA updates warnings for oral and injectable fluoroquinolone antibiotics due to disabling side effectsJuly 26, 2016Listen to This Podcast
Run Time:
00:3:00
Transcript
FDA strengthens kidney warnings for diabetes medicines canagliflozin (Invokana, Invokamet) and dapagliflozin (Farxiga, Xigduo XR)June 14, 2016Listen to This Podcast
Run Time:
00:3:04
Transcript
Update: FDA evaluating the risk of burns and scars with Zecuity (sumatriptan) migraine patchJune 10, 2016Listen to This Podcast
Run Time:
00:1:12
Transcript
FDA warns about serious heart problems with high doses of the antidiarrheal medicine loperamide (Imodium), including from abuse and misuseJune 7, 2016Listen to This Podcast
Run Time:
00:3:00
Transcript
FDA warns about serious bleeding risk with over-the-counter antacid products containing aspirinJune 6, 2016Listen to This Podcast
Run Time:
00:3:00
Transcript
FDA evaluating the risk of burns and scars with Zecuity (sumatriptan) migraine patchJune 2, 2016Listen to This Podcast
Run Time:
00:1:58
Transcript
FDA warns that prescribing of Nizoral (ketoconazole) oral tablets for unapproved uses including skin and nail infections continues; linked to patient deathMay 19, 2016Listen to This Podcast
Run Time:
00:3:00
Transcript
Interim clinical trial results find increased risk of leg and foot amputations, mostly affecting the toes, with the diabetes medicine canagliflozin (Invokana, Invokamet); FDA to investigateMay 18, 2016Listen to This Podcast
Run Time:
00:3:00
Transcript
FDA advises restricting fluoroquinolone antibiotic use for certain uncomplicated infections; warns about disabling side effects that can occur togetherMay 12, 2016Listen to This Podcast
Run Time:
00:3:00
Transcript
FDA warns about rare but serious skin reactions with mental health drug olanzapine (Zyprexa, Zyprexa Zydis, Zyprexa Relprevv, and Symbyax)May 10, 2016Listen to This Podcast
Run Time:
00:3:00
Transcript
FDA warns about new impulse-control problems associated with mental health drug aripiprazole (Abilify, Abilify Maintena, Aristada)May 3, 2016Listen to This Podcast
Run Time:
00:3:00
Transcript
FDA approves brand name change for antidepressant drug Brintellix (vortioxetine) to avoid confusion with antiplatelet drug Brilinta (ticagrelor)May 2, 2016Listen to This Podcast
Run Time:
00:3:00
Transcript
FDA to review study examining use of oral fluconazole (Diflucan) in pregnancyApril 26, 2016Listen to This Podcast
Run Time:
00:2:00
Transcript
FDA revises warnings regarding use of the diabetes medicine metformin in certain patients with reduced kidney functionApril 8, 2016Listen to This Podcast
Run Time:
00:3:00
Transcript
FDA announced that a safety review has found type 2 diabetes medicines containing saxagliptin and alogliptin may increase the risk of heart failureApril 5, 2016Listen to This Podcast
Run Time:
00:3:00
Transcript
FDA warns about several safety issues with opioid pain medicines; requires label changesMarch 29, 2016Listen to This Podcast
Run Time:
00:3:00
Transcript
FDA cautions about dosing errors when switching between different oral formulations of antifungal Noxafil (posaconazole); label changes approvedJanuary 4, 2016Listen to This Podcast
Run Time:
00:3:00
Transcript

View All Past Podcasts

Page Last Updated: 05/26/2017
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English